CGON

CG Oncology, Inc. (NASDAQ:CGON) is a clinical-stage biopharmaceutical company founded to develop innovative cancer treatments, specifically focusing on bladder cancer therapies. The company went public in 2024 and is headquartered in Irvine, California. CG Oncology represents a specialized approach to oncology drug development, concentrating on a single therapeutic area where significant unmet medical needs exist. The company is currently in clinical development phases and has not yet commercialized any products, operating as a pure-play research and development organization focused on advancing its lead drug candidate through regulatory approval processes.